文献速递支持与姑息治疗

中国湖北癌症合并COVID-19患者的临床特征、结局及死亡危险因素:多中心回顾性队列研究

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study.
PubMed 文献 · Lancet Oncol · 2020-05-29

该多中心回顾性队列研究纳入2020年1月13日至3月18日湖北9家医院205例实验室确诊SARS-CoV-2感染且病理确诊恶性肿瘤的患者,随访至4月20日。住院死亡率20%,血液系统恶性肿瘤患者死亡率高于实体瘤(41% vs 17%),症状出现前4周内接受化疗和男性是住院死亡的独立危险因素。

要点

  • 癌症合并COVID-19患者住院死亡率达20%,血液系统恶性肿瘤预后更差。
  • 症状出现前4周内接受化疗与男性是住院死亡的独立危险因素。
  • 常见实体瘤类型为乳腺癌、结直肠癌和肺癌。

核心结论

  • 癌症合并COVID-19住院患者病死率高,化疗后4周内及男性提示死亡高风险。

研究设计与样本

  • 回顾性多中心队列研究,纳入湖北9家医院205例实验室确诊SARS-CoV-2感染且病理确诊恶性肿瘤的患者,中位年龄63岁,随访至2020年4月20日。

主要发现

  • 205例患者中30例(15%)转入ICU,40例(20%)住院期间死亡。
  • 实体瘤中最常见为乳腺癌40例(20%)、结直肠癌28例(14%)、肺癌24例(12%)。
  • 182例患者中54例(30%)在症状出现前4周内接受抗肿瘤治疗。

临床怎么用

  • 对癌症合并COVID-19患者,尤其男性及近期化疗者,应加强死亡风险评估与监护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with cancer are a high-risk population in the COVID-19 pandemic. We aimed to describe clinical characteristics and outcomes of patients with cancer and COVID-19, and examined risk factors for mortality in this population. METHODS: We did a retrospective, multicentre, cohort study of 205 patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and with a pathological diagnosis of a malignant tumour in nine hospitals within Hubei, China, from Jan 13 to March 18, 2020. All patients were either discharged from hospitals or had died by April 20, 2020. Clinical characteristics, laboratory data, and cancer histories were compared between survivors and non-survivors by use of χ2 test. Risk factors for mortality were identified by univariable and multivariable logistic regression models. FINDINGS: Between Jan 13 and Mar 18, 2020, 205 patients with cancer and laboratory-confirmed SARS-CoV-2 infection were enrolled (median age 63 years [IQR 56-70; range 14-96]; 109 [53%] women). 183 (89%) had solid tumours and 22 (11%) had haematological malignancies. The median duration of follow-up was 68 days (IQR 59-78). The most common solid tumour types were breast (40 [20%] patients), colorectal (28 [14%]), and lung cancer (24 [12%]). 54 (30%) of 182 patients received antitumour therapies within 4 weeks before symptom onset. 30 (15%) of 205 patients were transferred to an intensive care unit and 40 (20%) died during hospital admission. Patients with haematological malignancies had poorer prognoses than did those with solid tumours: nine (41%) of 22 patients with haematological malignancies died versus 31 (17%) of 183 patients with solid tumours (hazard ratio for death 3·28 [95% CI 1·56-6·91]; log rank p=0·0009). Multivariable regression analysis showed that receiving chemotherapy within 4 weeks before symptom onset (odds ratio [OR] 3·51 [95% CI 1·16-10·59]; p=0·026) and male sex (OR 3·86 [95% CI 1·57-9·50]; p=0·0033) were risk factors for death during admission to hospital. INTERPRETATION: Patients with cancer and COVID-19 who were admitted to hospital had a high case-fatality rate. Unfavourable prognostic factors, including receiving chemotherapy within 4 weeks before symptom onset and male sex, might help clinicians to identify patients at high risk of fatal outcomes. FUNDING: National Natural Science Foundation of China.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020. PMID: 32479787. doi:10.1016/S1470-2045(20)30310-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。